Back to top
more

Celgene Corporation (CELG)

(Delayed Data from NSDQ)

$96.88 USD

96.88
5,654,306

+1.67 (1.75%)

Updated May 3, 2019 04:00 PM ET

After-Market: $96.84 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

5 Drug Stocks Well Poised to Beat Q2 Earnings Estimates

The NYSE ARCA Pharmaceutical Index has risen almost 9.8% year to date.

    Amgen's Myeloma Drug Improves Overall Survival in Phase III

    Biotech major, Amgen, Inc. (AMGN) announced final data from the phase III ASPIRE study, which showed that a combination regimen of its drug, Kyprolis, significantly improved overall survival (OS) in patients with relapsed multiple myeloma.

      Arpita Dutt headshot

      5 Pharma & Biotech Stocks That Could Be Big Winners in Q2 Earnings

      Here is a look at 5 pharma and biotech stocks including Merck (MRK) that are expected to post a positive earnings surprise in Q2.

        Arpita Dutt headshot

        Biotech Stock Roundup: Arena Shoots Up on Study Data, CELG Inks Immuno-Oncology Deal

        Arena (ARNA) saw it shares shoot up on mid-stage data on its pulmonary arterial hypertension drug while quite a few companies provided regulatory updates.

          Tirthankar Chakraborty headshot

          5 Top Multibagger Biotech Stocks to Buy in the 2nd Half

          Draconian crackdown on drug prices easing out and likelihood of a series of buyouts will help innovation starved biotech companies to gain in the second half.

            Prima Biomed's Intra-Tumor Study on Lead Candidate Approved

            Prima Biomed Ltd. (PBMD) announced that a new clinical study, INSIGHT, on its lead candidate IMP321 has received regulatory approval for initiation

              Celgene (CELG), BeiGene Team Up For PD-1 Inhibitor in China

              Celgene Corporation (CELG) recently entered into a strategic collaboration with China based-BeiGene, Ltd. (BGNE).

                Merck Falls as FDA Puts Hold on 3 Keytruda Myeloma Studies

                Merck & Co., Inc. (MRK) shares were down more than 1% in after-hours trading on Wednesday after the company announced that the FDA has placed a clinical hold on three combination studies of Keytruda in multiple myeloma, a form of blood cancer.

                  Why is Corcept's Stock Up More Than 60% So Far This Year?

                  Shares of Corcept Therapeutics Incorporated (CORT) has soared 62.5% this year so far, massively outperforming the 5.6% increase registered by the Zacks classified Medical Drugs industry during this period.

                    Agios/Celgene's Leukemia Candidate Positive in Phase I/II

                    Agios Pharmaceuticals, Inc. (AGIO) has announced a positive efficacy and safety data from the ongoing phase I/II study on experimental candidate IDHIFA (enasidenib) at an oral session at the European Hematology Association (EHA).

                      Epizyme Progressing Well on Two Lead Pipeline Candidates

                      We issued an updated research report on Epizyme, Inc. (EPZM) on Jun 23, 2017.

                        Small Cancer Biotech Space in Focus, 3 Stocks Up 100% & More

                        The oncology space has always been keenly watched by investors interested in the pharma/biotech sector.

                          Arpita Dutt headshot

                          Biotech Stock Roundup: Clovis Soars on Rubraca Data, Seattle Hit by Study Halt

                          Key highlights in the biotech sector include positive data on Clovis' (CLVS) PARP inhibitor, Rubraca.

                            Celgene Presents Interim Results from Cancer Drug Study

                            Celgene Corporation (CELG) announced encouraging results from an interim analysis of a phase IIIb study, MAGNIFY, on Revlimid.

                              The Zacks Analyst Blog Highlights: Apple, Procter & Gamble, Celgene, PayPal and Southern

                              The Zacks Analyst Blog Highlights: Apple, Procter & Gamble, Celgene, PayPal and Southern

                                J&J Immunotherapy Darzalex Ok'd for Expanded Combination Use

                                Johnson & Johnson (JNJ) announced that its immunotherapy, Darzalex has been approved for use in combination with Celgene Corporation's (CELG) multiple myeloma drug Pomalyst (pomalidomide) and dexamethasone.

                                  Sheraz Mian headshot

                                  Top Analyst Reports for Apple, Procter & Gamble, and Celgene

                                  Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), Procter & Gamble (PG), and Celgene (CELG).

                                    Celgene (CELG) Reports Data on Lupus Drug in Phase II Trial

                                    Celgene Corporation (CELG) announced results from the phase II trial, SLE-001 which evaluated lupus candidate, CC-220, at the Annual European Congress of Rheumatology (EULAR) 2017 in Madrid.

                                      Arpita Dutt headshot

                                      Biotech Stock Roundup: Management Changes at Biogen, Alexion, GILD Files HIV Drug

                                      Key highlights in the biotech sector include management changes for Biogen (BIIB) and Alexion as well as a regulatory filing for Gilead's HIV regimen.

                                        Acceleron (XLRN) Kidney Cancer Candidate Fails in Phase II

                                        Acceleron Pharma Inc.'s (XLRN) announced disappointing results from a phase II study evaluating its pipeline candidate dalantercept in combination with Pfizer's (PFE) Inlyta (axitinib) for treatment of advanced renal cell carcinoma (RCC).

                                          Merck Stalls Enrolment in Two Myeloma Studies of Keytruda

                                          Merck & Co., Inc. (MRK) announced that it is pausing two late-stage studies evaluating its anti-PD-1 therapy, Keytruda, as a combination therapy for the treatment of multiple melanoma, a form of blood cancer.

                                            Amgen's Multiple Myeloma Drug Receives NICE Recommendation

                                            Amgen Inc. (AMGN) announced that Kyprolis gained recommendation from National Institute for Health and Care Excellence (NICE) in combination with dexamethasone for the treatment of relapsed multiple myeloma.

                                              Celgene and Agios Announce Data on Idhifa for Leukemia

                                              Celgene Corporation (CELG) and Agios Pharmaceuticals, Inc. (AGIO) announced new efficacy and safety data on experimental candidate Idhifa (enasidenib).

                                                Celgene & Acceleron Complete Enrollment on Thalassemia Drug

                                                Celgene Corporation (CELG) and Acceleron Pharma Inc. (XLRN) announced that the companies have completed target enrollment in the phase III studies, MEDALIST and BELIEVE on pipeline candidate luspatercept.

                                                  Jazz Pharmaceuticals' Vyxeos NDA Granted Priority Review

                                                  Jazz Pharmaceuticals plc (JAZZ) announced that the New Drug Application (NDA) for its experimental leukemia candidate Vyxeos has been accepted for priority review by the FDA.